Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
| Autor: | Mohd W. Nasser, Imayavaramban Lakshmanan, Surinder K. Batra, Jawed A. Siddiqui, Ravi Salgia, Maneesh Jain, Shailendra Kumar Maurya, Apar Kishor Ganti, Parvez Khan |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
0301 basic medicine
Cancer Research Lung Neoplasms Disease medicine.disease_cause Article Epigenesis Genetic Metastasis 03 medical and health sciences 0302 clinical medicine Histone methylation Humans Medicine Epigenetics Lung cancer neoplasms business.industry Cancer DNA Methylation medicine.disease Small Cell Lung Carcinoma humanities respiratory tract diseases 030104 developmental biology 030220 oncology & carcinogenesis DNA methylation Cancer research Immunotherapy business Carcinogenesis |
| Zdroj: | Semin Cancer Biol |
| ISSN: | 1044-579X |
| DOI: | 10.1016/j.semcancer.2020.11.006 |
| Popis: | Small cell lung cancer (SCLC) is a particular subtype of lung cancer with high mortality. Recent advances in understanding SCLC genomics and breakthroughs of immunotherapy have substantially expanded existing knowledge and treatment modalities. However, challenges associated with SCLC remain enigmatic and elusive. Most of the conventional drug discovery approaches targeting altered signaling pathways in SCLC end up in the ‘grave-yard of drug discovery’, which mandates exploring novel approaches beyond inhibiting cell signaling pathways. Epigenetic modifications have long been documented as the key contributors to the tumorigenesis of almost all types of cancer, including SCLC. The last decade witnessed an exponential increase in our understanding of epigenetic modifications for SCLC. The present review highlights the central role of epigenetic regulations in acquiring neoplastic phenotype, metastasis, aggressiveness, resistance to chemotherapy, and immunotherapeutic approaches of SCLC. Different types of epigenetic modifications (DNA/histone methylation or acetylation) that can serve as predictive biomarkers for prognostication, treatment stratification, neuroendocrine lineage determination, and development of potential SCLC therapies are also discussed. We also review the utility of epigenetic targets/epidrugs in combination with first-line chemotherapy and immunotherapy that are currently under investigation in preclinical and clinical studies. Altogether, the information presents the inclusive landscape of SCLC epigenetics and epidrugs that will help translate the knowledge of epigenetics to improve SCLC outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect